Extended-release injectable buprenorphine videos & factsheets.

Buprenorphine is one of three medications (methadone and naltrexone being the other two) approved for use to treat opioid use disorder. It is available as a film or tablet, and more recently as two long-acting extended-release injectables. Sublocade™ was first to be approved by the FDA in November 2017. More recently, in May 2023, Brixadi™ received approval. In January 2024 it was added to the WA state Medicaid formulary.

Fewer clinicians have experience using Brixadi™ than Sublocade™. The videos, podcast, and information sheets on this page are intended to aid prescribers in their conversations with patients interested in these buprenorphine options.

Find the resources here.